← Leaderboards
Gregory R Mundy
University Of Texas Hlth Sci Ctr San Ant
$7,763,862
Attributed
$7,763,862
Total exposure
12
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.3M · FY2005–12$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$34,075,939 · 14
VA$0 · 1
By mechanism
M01$14,768,372 · 1
P01$9,911,021 · 3
R01$3,956,318 · 4
P30$2,834,018 · 1
P50$1,531,425 · 1
U54$675,371 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Xiaodu Wang$4,457,592
- Theresa A Guise$8,674,181
- Sakamuri V. Reddy$2,018,756
- Jean X Jiang$13,187,441
Others in their field
Top investigators on “Bone Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$238,799,659
- Charles A Coltman · Southwest Oncology Group$142,913,801
- Richard L Schilsky · University Of Chicago$50,742,272
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$48,601,153
- Gregory H Reaman · National Childhood Cancer Foundation$46,932,541
- Mary M Horowitz · Medical College Of Wisconsin$33,803,638
Research focus
Bone NeoplasmsNeoplastic GrowthSiteResearch StudyClinical ResearchTumor BurdenBreast Cancer CellCellsLeadHypercalcemiaBaseMediatingIn VitroBone ResorptionOsteoclastsIn VivoSkeletonBone DisorderOsteolysisCancer CellMalignant NeoplasmsMultiple MyelomaLifeLytic Metastatic Lesion
Grant awards (69)
Cellular Mechanisms of Bone Quality in Metastatic Breast Cancer$335,794
P50 · FY2012 · CA · contact PI
TGF-Beta Bone Fragility at the Tumor-Bone Interface in Myeloma$0
I01 · FY2012 · VA · contact PI
Cellular Mechanisms of Bone Quality in Metastatic Breast Cancer$319,481
P50 · FY2011 · CA · contact PI
TGF-Beta Bone Fragility at the Tumor-Bone Interface in Myeloma$0
I01 · FY2011 · VA · contact PI
Cellular Mechanisms of Bone Quality in Metastatic Breast Cancer$320,738
P50 · FY2010 · CA · contact PI
The Gli Family of Transcriptional Activators & Breast Cancer Mediated Osteolysis$216,714
P01 · FY2010 · CA · contact PI
Cellular Mechanisms of Bone Quality in Metastatic Breast Cancer$337,410
P50 · FY2009 · CA · contact PI
The Gli Family of Transcriptional Activators & Breast Cancer Mediated Osteolysis$241,192
P01 · FY2009 · CA · contact PI
Gli Control of PTH-rP and Osteolysis in Breast Cancer$171,406
R01 · FY2009 · CA · contact PI
Effect of Tumors on the Skeleton$61,472
P01 · FY2009 · CA · contact PI
TGF-Beta Bone Fragility at the Tumor-Bone Interface in Myeloma$0
I01 · FY2009 · VA · contact PI
Effect of Tumors on the Skeleton$1,133,920
P01 · FY2008 · CA · contact PI
THE UBIQUITIN-PROTEOSOME PATHWAY AND BMP-2 EXPRESSION$251,037
R01 · FY2008 · AR · contact PI
Host Microenvironment and Bone Metastases$245,335
U54 · FY2008 · CA · contact PI
Cellular Mechanisms of Bone Quality in Metastatic Breast Cancer$218,002
P50 · FY2008 · CA · contact PI
The Gli Family of Transcriptional Activators & Breast Cancer Mediated Osteolysis$212,591
P01 · FY2008 · CA · contact PI
Gli Control of PTH-rP and Osteolysis in Breast Cancer$171,406
R01 · FY2008 · CA · contact PI
Effect of Tumors on the Skeleton$1,130,480
P01 · FY2007 · CA · contact PI
Effects of the Mevalonate Pathway on Bone Formation$299,742
R01 · FY2007 · AR · contact PI
Host Microenvironment and Bone Metastases$259,314
U54 · FY2007 · CA · contact PI
THE UBIQUITIN-PROTEOSOME PATHWAY AND BMP-2 EXPRESSION$256,161
R01 · FY2007 · AR · contact PI
The Gli Family of Transcriptional Activators & Breast Cancer Mediated Osteolysis$212,483
P01 · FY2007 · CA · contact PI
Gli Control of PTH-rP and Osteolysis in Breast Cancer$171,313
R01 · FY2007 · CA · contact PI
Effect of Tumors on the Skeleton$1,130,748
P01 · FY2006 · CA · contact PI
THE UBIQUITIN-PROTEOSOME PATHWAY AND BMP-2 EXPRESSION$262,952
R01 · FY2006 · AR · contact PI
Effects of the Mevalonate Pathway on Bone Formation$203,062
R01 · FY2006 · AR · contact PI
Host Microenvironment and Bone Metastases$170,722
U54 · FY2006 · CA · contact PI
Gli Control of PTH-rP and Osteolysis in Brest Cancer$146,624
R01 · FY2006 · CA · contact PI
The Gli Family of Transcriptional Activators and Breast Cancer Mediated Osteolysi$136,840
P01 · FY2006 · CA · contact PI
Gli Control of PTH-rP and Osteolysis in Brest Cancer$109,500
R01 · FY2006 · CA · contact PI
Effects of the Mevalonate Pathway on Bone Formation$100,000
R01 · FY2006 · AR · contact PI
GENERAL CLINICAL RESEARCH CENTER$3,440,232
M01 · FY2005 · RR
Effects of the Mevalonate Pathway on Bone Formation$328,215
R01 · FY2005 · AR
Gli Control of PTH-rP and Osteolysis in Breast Cancer$288,350
R01 · FY2005 · CA
THE UBIQUITIN-PROTEASOME PATHWAY AND BMP-2 EXPRESSION$256,960
R01 · FY2005 · AR
GENERAL CLINICAL RESEARCH CENTER$3,296,188
M01 · FY2004 · RR
SAN ANTONIO CANCER INSTITUTE$2,834,018
P30 · FY2004 · CA
Effects of the Mevalonate Pathway on Bone Formation$354,050
R01 · FY2004 · AR
TUMORS EFFECTS ON THE SKELETON$119,113
P01 · FY2004 · CA
TUMORS EFFECTS ON THE SKELETON$11,499
P01 · FY2004 · CA
IVth Intl Conference on Cancer-Induced Bone Diseases$11,000
R13 · FY2004 · CA
GENERAL CLINICAL RESEARCH CENTER$3,749,344
M01 · FY2003 · RR
TUMORS EFFECTS ON THE SKELETON$1,158,090
P01 · FY2003 · CA
Effects of the Mevalonate Pathway on Bone Formation$354,050
R01 · FY2003 · AR
TUMORS EFFECTS ON THE SKELETON$134,240
P01 · FY2003 · CA
GCRC BIostatistics and Informatics Core$132,696
M01 · FY2003 · RR
TUMORS EFFECTS ON THE SKELETON$115,644
P01 · FY2003 · CA
GENERAL CLINICAL RESEARCH CENTER$2,216,758
M01 · FY2002 · RR
TUMORS EFFECTS ON THE SKELETON$1,199,020
P01 · FY2002 · CA
GCRC Imaging Core Supplement$298,105
M01 · FY2002 · RR
TUMORS EFFECTS ON THE SKELETON$130,181
P01 · FY2002 · CA
TUMORS EFFECTS ON THE SKELETON$112,146
P01 · FY2002 · CA
TRAINING PROGRAM IN BONE AND MINERAL METABOLISM$84,416
T32 · FY2002 · AR
TUMORS EFFECTS ON THE SKELETON$66,169
P01 · FY2002 · CA
Effects of bisphosphonates to decrease tumor burden$0
P01 · FY2002 · CA
Effects of bisphosphonates to decrease tumor burden$0
P01 · FY2002 · CA
Effects of bisphosphonates to decrease tumor burden$0
P01 · FY2002 · CA
Effects of bisphosphonates to decrease tumor burden$0
P01 · FY2002 · CA
GENERAL CLINICAL RESEARCH CENTER$1,635,049
M01 · FY2001 · RR
TUMORS EFFECTS ON THE SKELETON$1,096,367
P01 · FY2001 · CA
TUMORS EFFECTS ON THE SKELETON$43,750
P01 · FY2001 · CA
TRAINING PROGRAM IN BONE AND MINERAL METABOLISM$28,696
T32 · FY2001 · AR
Effects of bisphosphonates to decrease tumor burden$0
P01 · FY2001 · CA
Effects of bisphosphonates to decrease tumor burden$0
P01 · FY2001 · CA
TUMORS EFFECTS ON THE SKELETON$1,066,848
P01 · FY2000 · CA
CYTOKINES AND BONE CELL FUNCTION$231,490
R01 · FY2000 · AR
MASTER OF SCIENCE DEGREE IN CLINICAL INVESTIGATION$199,752
K30 · FY2000 · HL
Effects of bisphosphonates to decrease tumor burden$181,514
P01 · FY2000 · CA
TRAINING PROGRAM IN BONE AND MINERAL METABOLISM$75,550
T32 · FY2000 · AR